NASDAQ:LFCR Lifecore Biomedical (LFCR) Stock Price, News & Analysis $8.03 -0.01 (-0.12%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lifecore Biomedical Stock (NASDAQ:LFCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lifecore Biomedical alerts:Sign Up Key Stats Today's Range$7.93▼$8.1250-Day Range$6.36▼$8.3452-Week Range$3.68▼$8.63Volume55,721 shsAverage Volume228,151 shsMarket Capitalization$297.31 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingModerate Buy Company Overview Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota. Read More Lifecore Biomedical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreLFCR MarketRank™: Lifecore Biomedical scored higher than 21% of companies evaluated by MarketBeat, and ranked 2290th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingModerate Buy Consensus RatingLifecore Biomedical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageLifecore Biomedical has only been the subject of 1 research reports in the past 90 days.Read more about Lifecore Biomedical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.91) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lifecore Biomedical is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lifecore Biomedical is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLifecore Biomedical has a P/B Ratio of 21.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lifecore Biomedical's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.04% of the float of Lifecore Biomedical has been sold short.Short Interest Ratio / Days to CoverLifecore Biomedical has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Lifecore Biomedical has recently decreased by 0.86%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLifecore Biomedical does not currently pay a dividend.Dividend GrowthLifecore Biomedical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.04% of the float of Lifecore Biomedical has been sold short.Short Interest Ratio / Days to CoverLifecore Biomedical has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Lifecore Biomedical has recently decreased by 0.86%, indicating that investor sentiment is improving. News and Social Media1.1 / 5News SentimentN/A Search Interest1 people have searched for LFCR on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Lifecore Biomedical to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lifecore Biomedical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,824,031.00 in company stock.Percentage Held by Insiders32.20% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.36% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lifecore Biomedical's insider trading history. Receive LFCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address LFCR Stock News HeadlinesLifecore Biomedical: Inflecting Financials Over Next 3 YearsJune 18, 2025 | seekingalpha.comLifecore Biomedical signs new 10-year commercial manufacturing and supply agreementJune 17, 2025 | msn.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 4 at 2:00 AM | Brownstone Research (Ad)Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing CustomerJune 17, 2025 | globenewswire.comLifecore Receives Full Payment Early For $17 Mln Equipment SaleJune 14, 2025 | nasdaq.comLifecore Biomedical, Inc.: Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment SaleJune 12, 2025 | finanznachrichten.deLifecore Biomedical receives accelerated payment of remaining $10M in proceeds from equipment saleJune 12, 2025 | msn.comLifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment SaleJune 12, 2025 | globenewswire.comSee More Headlines LFCR Stock Analysis - Frequently Asked Questions How have LFCR shares performed this year? Lifecore Biomedical's stock was trading at $7.43 on January 1st, 2025. Since then, LFCR stock has increased by 8.1% and is now trading at $8.03. How were Lifecore Biomedical's earnings last quarter? Lifecore Biomedical, Inc. (NASDAQ:LFCR) posted its quarterly earnings data on Thursday, April, 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.05. The business earned $35.15 million during the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical had a negative net margin of 35.90% and a negative trailing twelve-month return on equity of 551.09%. Read the conference call transcript. How do I buy shares of Lifecore Biomedical? Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lifecore Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lifecore Biomedical investors own include JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings4/03/2025Today7/04/2025Next Earnings (Estimated)8/15/2025Fiscal Year End5/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LFCR CIK1005286 Webwww.lifecore.com Phone(800) 454-1355Fax650-368-9818Employees690Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside-0.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$12.01 million Net Margins-35.90% Pretax Margin-34.31% Return on Equity-551.09% Return on Assets-13.89% Debt Debt-to-Equity Ratio66.36 Current Ratio2.71 Quick Ratio1.59 Sales & Book Value Annual Sales$130.31 million Price / Sales2.28 Cash FlowN/A Price / Cash FlowN/A Book Value$0.37 per share Price / Book21.70Miscellaneous Outstanding Shares37,025,000Free Float25,103,000Market Cap$297.31 million OptionableOptionable Beta0.71 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:LFCR) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifecore Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifecore Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.